RT Journal Article
SR Electronic
T1 The prognostic value of mean platelet volume in patients with coronary artery disease: a systematic review with meta-analyses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.20.24304646
DO 10.1101/2024.03.20.24304646
A1 Galimzhanov, Akhmetzhan
A1 Naung Tun, Han
A1 Sabitov, Yersin
A1 Perone, Francesco
A1 Kursat, Tigen Mustafa
A1 Tenekecioglu, Erhan
A1 Mamas, Mamas A
YR 2024
UL http://medrxiv.org/content/early/2024/03/22/2024.03.20.24304646.abstract
AB Background Mean platelet volume (MPV) is a widely available laboratory index, however its prognostic significance in patients with coronary artery disease (CAD) is still unclear. We intended to investigate and pool the evidence on the prognostic utility of admission MPV in predicting clinical outcomes in patients with CAD.Methods PubMed, Web of Science, and Scopus were the major databases used for literature search. The risk of bias was assessed using the quality in prognostic factor studies. We used random-effects pairwise analysis with the Knapp and Hartung approach supported further with permutation tests and prediction intervals (PIs).Results We identified 52 studies with 47066 patients. A meta-analysis of 9 studies with 14,864 patients demonstrated that 1 femtoliter increase in MPV values was associated with a rise of 29% in the risk of long-term mortality (hazard ratio (HR) 1.29, 95% confidence interval (CI) 1.22-1.37) in CAD as a whole. The results were further supported with PIs, permutation tests and leave-one-out sensitivity analyses. MPV also demonstrated its stable and significant prognostic utility in predicting long-term mortality as a linear variable in patients treated with percutaneous coronary intervention (PCI) and presented with acute coronary syndrome (ACS) (HR 1.29, 95% CI 1.20-1.39, and 1.29, 95% CI 1.19-1.39, respectively).Conclusion The meta-analysis found robust evidence on the link between admission MPV and the increased risk of long-term mortality in patients with CAD patients, as well as in patients who underwent PCI and patients presented with ACS.PROSPERO number CRD42023495287Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023495287 Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis is a systematic review and meta-analysis based on the data from the primary studies